apl. Prof. Dr. Lucie Heinzerling



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Centrosomal protein TRIM43 restricts herpesvirus infection by regulating nuclear lamina integrity (2019) Full F, Van Gent M, Sparrer KMJ, Chiang C, Zurenski MA, Scherer M, Brockmeyer NH, et al. Journal article Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- nd RIG-1 agonist in patients with advanced solid tumors (2018) Terheyden P, Weishaupt C, Heinzerling L, Klinkhardt U, Krauss J, Mohr P, Kiecker F, et al. Conference contribution BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy (2018) Dörrie J, Babalija L, Hoyer S, Gerer KF, Schuler G, Heinzerling L, Schaft N Journal article Braf inhibitors and radiation do not act synergistically to inhibit WT and V600E BRAF human melanoma (2018) Walter L, Heinzerling L Journal article, Original article A web platform for the network analysis of high-throughput data in melanoma and its use to investigate mechanisms of resistance to anti-PD1 immunotherapy (2018) Dreyer F, Cantone M, Eberhardt M, Jaitly T, Walter L, Wittmann J, Gupta S, et al. Journal article, Original article Eosinophil-cationic protein: A novel liquid prognostic biomarker in melanoma (2018) Moreira A, Krueckel A, Schuler G, Heinzerling L Conference contribution Characterization of Checkpoint Inhibitor-associated Diabetes mellitus - Experience in 12 Patients (2018) Satzger I, Momma M, Thoms KM, Eigentler T, Schultz E, Loquai C, Zimmer L, et al. Conference contribution Anti-PD-1 Therapy in SUFU mutant Patients with Gorlin-Goltz Syndrome (2018) Moreira A, Kirchberger MC, Toussaint F, Erdmann M, Schuler G, Heinzerling L Conference contribution BRAF and MEK inhibitors change human immune cell phenotype and function; possible consequences for combination therapy (2018) Hoyer S, Eberlein V, Babalija L, Gerer K, Walter L, Schuler G, Schaft N, et al. Conference contribution Neuromuscular Side Effects of Immune Checkpoint Inhibitors (2018) Moreira A, Loquai C, Knauss S, Gutzmer R, Dimitriou F, Meier F, Heppt M, et al. Conference contribution